ADMA Biologics Files 8-K on Operations & Financial Condition
Ticker: ADMA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, corporate-governance
TL;DR
**ADMA Biologics filed an 8-K for financial results, stay tuned for details.**
AI Summary
ADMA Biologics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing is a standard disclosure and does not contain specific new financial figures or events, but rather indicates that such information will be provided. For investors, this means that detailed financial updates are forthcoming, which could impact stock valuation depending on the nature of the results.
Why It Matters
This filing signals that ADMA Biologics is preparing to release or has released information regarding its financial performance, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This 8-K is a routine filing indicating future financial disclosures, not an event that inherently carries high risk.
Analyst Insight
A smart investor would monitor for subsequent filings or press releases from ADMA Biologics, Inc. that provide the actual 'Results of Operations and Financial Condition' mentioned in this 8-K, as these will contain the specific financial data needed for analysis.
Key Numbers
- 2024-01-08 — Date of Report (The date the earliest event reported in the 8-K occurred.)
- 001-36728 — Commission File Number (The SEC file number for ADMA Biologics, Inc.)
- (201) 478-5552 — Business Phone Number (The primary contact number for ADMA Biologics, Inc.)
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for ADMA Biologics
- 001-36728 (dollar_amount) — Commission File Number
- 56-2590442 (dollar_amount) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing by ADMA Biologics, Inc.?
The primary purpose of this 8-K filing, dated January 8, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.
What is the state of incorporation for ADMA Biologics, Inc.?
ADMA Biologics, Inc. is incorporated in Delaware, as indicated in the filing under 'Delaware (State or other jurisdiction of incorporation)'.
Is ADMA Biologics, Inc. classified as an 'emerging growth company'?
The filing indicates that ADMA Biologics, Inc. is an 'Emerging growth company' by checking the appropriate box, but it does not indicate if they have elected not to use the extended transition period.
What is the business address of ADMA Biologics, Inc. as listed in the filing?
The business address of ADMA Biologics, Inc. is 465 State Route 17, Ramsey, New Jersey 07446, according to the filing.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-08 07:30:30
Filing Documents
- ef20018240_8k.htm (8-K) — 29KB
- ef20018240_ex99-1.htm (EX-99.1) — 30KB
- image0.jpg (GRAPHIC) — 7KB
- 0001140361-24-001194.txt ( ) — 210KB
- adma-20240108.xsd (EX-101.SCH) — 4KB
- adma-20240108_lab.xml (EX-101.LAB) — 22KB
- adma-20240108_pre.xml (EX-101.PRE) — 16KB
- ef20018240_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition On January 8, 2024, ADMA Biologics, Inc. (the "Company") issued a press release announcing the Company's preliminary unaudited fourth quarter and full year 2023 revenues and providing a business update.*
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. Press Release, dated January 8, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. January 8, 2024 ADMA Biologics, Inc. By: /s/ Brian Lenz Name: Brian Lenz Title: Executive Vice President and Chief Financial Officer